Research programme: infectious disease therapeutics - Johnson & Johnson

Drug Profile

Research programme: infectious disease therapeutics - Johnson & Johnson

Latest Information Update: 10 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Johnson & Johnson
  • Developer Johnson & Johnson; National Institutes of Health (USA); University of California, San Diego; Walter and Eliza Hall Institute of Medical Research
  • Class Antimalarials; Antiparasitics; Antituberculars; Gene-directed enzyme-prodrug therapies; Small molecules
  • Mechanism of Action Gene modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Chagas disease; Malaria; Tuberculosis

Most Recent Events

  • 15 Jun 2017 Early research in Chagas'-disease in USA (unspecified route)
  • 15 Jun 2017 Early research in Malaria in USA (unspecified route)
  • 15 Jun 2017 Early research in Tuberculosis in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top